Skip to content

Zai Lab Zeluja OKd in China for 1st-line maintenance treatment of ovarian cancer

September 10, 2020

The China National Medical Products Administration has approved Zai Lab’s (NASDAQ:ZLAB) supplemental New Drug Application (sNDA) for ZEJULA (niraparib), an oral, once-daily poly (ADP-ribose) polymerase (PARP) inhibitor, as a maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy.

ZEJULA is also being evaluated in China for the treatment of patients with advanced or metastatic gastric cancer who failed prior treatment.

From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: